<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684043</url>
  </required_header>
  <id_info>
    <org_study_id>H-2009-042-1155</org_study_id>
    <nct_id>NCT04684043</nct_id>
  </id_info>
  <brief_title>Prognostic Implications of Physiologic Investigation After Revascularization With Stent</brief_title>
  <acronym>POST-PCI FLOW</acronym>
  <official_title>Prognostic Implications of Physiologic Investigation After Revascularization With Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bon-Kwon Koo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inje University Ilsan Paik Hospital, Goyang, South Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing First Hospital, Nanjing Medical University, Nanjing, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tsuchiura Kyodo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGovern Medical School at UTHealth and Memorial Hermann Hospital, TX, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagoya City University Graduate School of Medical Science, Nagoya, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers Robert Wood Johnson Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Raffaele Scientific Institute, Milan, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University Hospital, Suwon, South Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyoto Second Red Cross Hospital, Kyoto, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo Medical University Hachioji Medical Center, Tokyo, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous coronary intervention (PCI) is a standard treatment strategy for coronary artery&#xD;
      disease (CAD). With the presence of myocardial ischemia, PCI reduces the risks of death,&#xD;
      myocardial infarction (MI) and revascularization compared to medical therapy. However, the&#xD;
      risk of future clinical events remains high, and about 10% of patients experienced further&#xD;
      cardiovascular events after PCI. Several factors are associated with these poor outcomes.&#xD;
      Well known patient-related risk factors are diabetes mellitus, chronic kidney disease, left&#xD;
      ventricular dysfunction, previous MI, and presentation with the acute coronary syndrome.&#xD;
      Procedure-related factors, such as stent underexpension, malapposition, edge dissection, the&#xD;
      number of the used stent, and total stent length, are also related to poor prognosis after&#xD;
      PCI. Recent studies reported that fractional flow reserve (FFR) after coronary stenting, or&#xD;
      post PCI FFR, was associated with future clinical outcomes after PCI, and low post PCI FFR&#xD;
      value was associated with procedural factors. However, optimal cut-off values of post-PCI FFR&#xD;
      ranged widely, from 0.86 to 0.96, and some study reported the limited prognostic value of&#xD;
      post-PCI FFR. This might result from differences in study populations, the definition of&#xD;
      outcomes, type of stent used, and distribution of included vessels among previous studies.&#xD;
&#xD;
      To establish the clinical relevance of post-PCI FFR and to evaluate the useful cut-off value&#xD;
      of post-PCI FFR in daily practice, investigators planned to incorporate all previous evidence&#xD;
      of post-PCI FFR by collaboration with international researchers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study population was incorporated from studies which were already published.&#xD;
      Investigators will incorporate all known registries to the POST-PCI FLOW registry by&#xD;
      requesting data from principal investigator of each registry.&#xD;
&#xD;
      Investigators will perform systemic review of the previous published data and an updated&#xD;
      patient-level meta-analysis of studies, including the most recent publications. PubMed,&#xD;
      EMBASE, Cochrane Central Register of Controlled Trials, the United States National Institutes&#xD;
      of Health registry of clinical trials, and relevant websites were searched for pertinent&#xD;
      published studies. The electronic search strategy was complemented by manual examination of&#xD;
      references cited by included articles, recent reviews, editorials, and meta-analyses. No&#xD;
      restrictions were imposed on language, study period, or sample size. Searching key words&#xD;
      included 'post', 'after', 'PCI', 'Percutaneous coronary intervention', 'coronary stenting',&#xD;
      'stenting', 'stent', 'stent implantation', 'FFR', and 'fractional flow reserve'.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>2 years</time_frame>
    <description>A composite of cardiac death, target vessel myocardial infarction and target vessel revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or myocardial infarction</measure>
    <time_frame>2 years</time_frame>
    <description>a composite of cardiac death and target vessel myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel myocardial infarction</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cut-off value of post-PCI FFR</measure>
    <time_frame>2 years</time_frame>
    <description>Define the best cut-off value for predicting the future adverse events</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5100</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Post PCI state</arm_group_label>
    <description>The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>PCI was performed using drug-eluting stents</description>
    <arm_group_label>Post PCI state</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were diagnosed as obstructive coronary artery disease and treated by DES and&#xD;
        measured post PCI FFR after PCI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Articles were included when they met the following prespecified criteria: (1) included the&#xD;
        patients who underwent PCI with drug-eluting stent (DES); (2) post-PCI FFR was measured&#xD;
        after DES implantation; (3) pre-PCI FFR measurement was not mandatory for article&#xD;
        inclusion; (4) patients were followed up at least 6 months; (5) clinical outcomes,&#xD;
        including all-cause death, cardiac death, target vessel myocardial infarction (TVMI) or&#xD;
        target vessel revascularization (TVR), were clearly reported; (6) randomized controlled&#xD;
        trials or non-randomized prospective or retrospective registries were included. Two&#xD;
        independent investigators screened titles and abstracts, identified duplicated studies,&#xD;
        performed full-article reviews, and determined the studies' inclusion. The third&#xD;
        investigator supervised the searching process and adjudicated all the disagreements.&#xD;
&#xD;
          -  Patients with life expectancy &lt; 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bon-Kwon Koo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital, Seoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joon Hyung MD, PhD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University Ilsan Paik Hospital, Goyang, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shao-Liang Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University, Nanjing, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tsunekazu Kakuta, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tsuchiura Kyodo General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nils P. Johnson, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGovern Medical School at UTHealth and Memorial Hermann Hospital, TX, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tsuyoshi Ito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nagoya City University Graduate School of Medical Science, Nagoya, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdul Hakeem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Robert Wood Johnson Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard De Bruyne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorenzo Azzalini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Raffaele Scientific Institute, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong-Seok Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University Hospital, Suwon, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massoud A. Leesar, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akiko Matsuo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto Second Red Cross Hospital, Kyoto, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nobuhiro Tanaka, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokyo Medical University Hachioji Medical Center, Tokyo, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo Myung Lee, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bon-Kwon Koo, MD, PhD</last_name>
    <phone>82-2-2072-2062</phone>
    <email>bkkoo@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doyeon Hwang, MD</last_name>
    <phone>82-10-7446-2779</phone>
    <email>cardiol.intv@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Select</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bon-Kwon Koo, MD, PhD</last_name>
      <phone>+82-1033561869</phone>
      <email>bkkoo@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Seokhun Yang, MD</last_name>
      <phone>+82-1025953470</phone>
      <email>newturnz7@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bon-Kwon Koo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. Erratum in: Eur Heart J. 2019 Oct 1;40(37):3096.</citation>
    <PMID>30165437</PMID>
  </reference>
  <reference>
    <citation>Fearon WF, Nishi T, De Bruyne B, Boothroyd DB, Barbato E, Tonino P, Jüni P, Pijls NHJ, Hlatky MA; FAME 2 Trial Investigators. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2018 Jan 30;137(5):480-487. doi: 10.1161/CIRCULATIONAHA.117.031907. Epub 2017 Nov 2.</citation>
    <PMID>29097450</PMID>
  </reference>
  <reference>
    <citation>Hwang D, Lee JM, Lee HJ, Kim SH, Nam CW, Hahn JY, Shin ES, Matsuo A, Tanaka N, Matsuo H, Lee SY, Doh JH, Koo BK. Influence of target vessel on prognostic relevance of fractional flow reserve after coronary stenting. EuroIntervention. 2019 Aug 29;15(5):457-464. doi: 10.4244/EIJ-D-18-00913.</citation>
    <PMID>30561367</PMID>
  </reference>
  <reference>
    <citation>Li SJ, Ge Z, Kan J, Zhang JJ, Ye F, Kwan TW, Santoso T, Yang S, Sheiban I, Qian XS, Tian NL, Rab TS, Tao L, Chen SL. Cutoff Value and Long-Term Prediction of Clinical Events by FFR Measured Immediately After Implantation of a Drug-Eluting Stent in Patients With Coronary Artery Disease: 1- to 3-Year Results From the DKCRUSH VII Registry Study. JACC Cardiovasc Interv. 2017 May 22;10(10):986-995. doi: 10.1016/j.jcin.2017.02.012. Epub 2017 Apr 26.</citation>
    <PMID>28456699</PMID>
  </reference>
  <reference>
    <citation>Rimac G, Fearon WF, De Bruyne B, Ikeno F, Matsuo H, Piroth Z, Costerousse O, Bertrand OF. Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis. Am Heart J. 2017 Jan;183:1-9. doi: 10.1016/j.ahj.2016.10.005. Epub 2016 Oct 11. Review.</citation>
    <PMID>27979031</PMID>
  </reference>
  <reference>
    <citation>van Zandvoort LJC, Masdjedi K, Witberg K, Ligthart J, Tovar Forero MN, Diletti R, Lemmert ME, Wilschut J, de Jaegere PPT, Boersma E, Zijlstra F, Van Mieghem NM, Daemen J. Explanation of Postprocedural Fractional Flow Reserve Below 0.85. Circ Cardiovasc Interv. 2019 Feb;12(2):e007030. doi: 10.1161/CIRCINTERVENTIONS.118.007030.</citation>
    <PMID>30732469</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Bon-Kwon Koo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>fractional flow reserve</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>drug-eluting stent</keyword>
  <keyword>coronary atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

